Supplementary Material

eTable 1. Search Strategy
eTable 2. Newcastle–Ottawa Scale Scores for All Included Studies
eTable 3. Baseline Characteristics of the Included Studies
eFigure 1. PALS by study

eTable 1. Search Strategy

Search strategy:
PubMed/MEDLINE, Scopus, Lilacs
"Amyloidosis, Hereditary, Transthyretin-Related" [Supplementary Concept] **OR** "hereditary transthyretin amyloidosis" OR "Transthyretin amyloidosis" OR "ATTR amyloidosis" OR "Amyloid Neuropathies, Familial"[Mesh]
AND
"Atrial Function, Left"[Mesh] OR “Left Atrial Function” OR “Function, Left Atrial” OR “Functions, Left Atrial” OR “Left Atrial Functions” OR "left atrial strain" OR "speckle tracking" OR "strain imaging"
EMBASE (ENTREE)
'hereditary transthyretin amyloidosis'/exp OR 'familial attr amyloidosis' OR 'familial ttr amyloidosis' OR 'familial transthyretin amyloidosis' OR 'familial transthyretin-related amyloidosis' OR 'hattr amyloidosis' OR 'hereditary attr amyloidosis' OR 'hereditary ttr amyloidosis' OR 'hereditary ttr-related amyloidosis' OR 'hereditary transthyretin amyloidosis' OR 'transthyretin-related hereditary amyloidosis' OR 'familial amyloid polyneuropathy'/exp OR 'amyloid neuropathies, familial' OR 'amyloid neuropathy, hereditary' OR 'amyloid polyneuropathy, familial' OR 'amyloidosis, hereditary neuropathic' OR 'familial amyloid neuropathies' OR 'familial amyloid neuropathy' OR 'familial amyloid polyneuropathy' OR 'familial amyloidotic polyneuropathy' OR 'familial neuropathic amyloidosis' OR 'familial polyneuropathic amyloidosis' OR 'hereditary amyloid neuropathy' OR 'hereditary amyloid polyneuropathy' OR 'hereditary neuropathic amyloidosis' OR 'neuropathic amyloidosis, hereditary'
AND
'left atrial function'/exp OR 'atrial function, left' OR 'left atrial function' OR 'left atrium function' OR 'speckle tracking echocardiography'/exp OR 'speckle tracking echocardiography' OR ‘left atrial strain’ OR ‘strain imaging’

eTable 2. Methodological Quality Assessment – Newcastle–Ottawa Scale (NOS)

Study	Selection (0–4)	Comparability (0–2)	Outcome (0–3)	Total	Quality
Aceves Velazquez	3	1	2	6	Moderate
Bandera et al.	4	2	3	9	High
Di Bella et al.	3	1	2	6	Moderate
Di Lisi et al. (2023)	3	1	2	6	Moderate
Di Lisi et al. (2024)	3	1	2	6	Moderate
de Gregorio et al.	3	1	2	6	Moderate
Nochioka et al.	4	2	3	9	High
Henein et al.	3	1	2	6	Moderate
Trimarchi et al.	2	1	2	5	Moderate

eTable 3. Baseline Characteristics of Included Studies

Study (year)	Subgroup	N	ATTRv variant(s)	Age (years)	Male (%)	Cardiac involvement	Neuropathy
Bandera et al. (2022)	Val60Ala (V60A)	93	Val60Ala	66 ± 7	65,5	Yes	No
Bandera et al. (2022)	Val122Ile (V122I)	241	Val122Ile	76 ± 7	70,1	Yes	No
Bandera et al. (2022)	Other variants	21	Glu89Gln; Phe64Leu; Thr49Ala	62 ± 12	81	Yes	No
De Gregorio et al. (2016)	Total	16	Glu89Gln; Phe64Leu; Thr49Ala	57.7±9.8	81	Yes	Yes
Di Bella et al. (2016)	Total	28	Glu89Gln; Phe64Leu; Thr49Ala; Glu89Gln+Gly6Ser	53 ±12	57	No	Yes
Di Lisi et al. (2023)	Total	31	Phe64Leu; Val122Ile; Glu89Gln; His110Asn; Ser97Phe	61,9 ±10,7	64,5	Yes [1]	Yes [2]
Di Lisi et al. (2024)	Cardiac phenotype	7	Phe64Leu; Glu89Gln; Ser97Phe	66 ± 8	100	Yes	No
Di Lisi et al. (2024)	Neurological phenotype	14	Phe64Leu; Val122Ile; His110Asn	65,7 ± 7,8	29	No	Yes
Henein et al.	Total	46	Val30Met Ala45Ser	63 ±14	65	No	No

Nochioka et al. (2017)	Total	29	Ile68Leu; Glu89Gln; Val122Ile; Thr60Ala; Thr49Ala; Val30Met; outras	59,1 ± 13,1	69	Yes	No
Trimarchi et al. (2023)	Total	20	Val30Met; Val122Ile; Glu89Gln; Phe64Leu	74 ± 6	100	Yes	–
Aceves-Velazquez et al. (2020)	Total	30	Dados não informados	–	–	–	–

[1] Subgroup with cardiac amyloidosis and polyneuropathy [2] Subgroup with polyneuropathy

eFigure 1. PALS (%) by study.

